FDA Brief

Warning letters Drugs

FDA warning letter to

Trinity HealthCare Supply, LLC dba altRx

LowIssued Jun 8Posted Jun 16Center for Drug Evaluation and Research (CDER)

FDA warns altRx over misleading website claims for compounded semaglutide and tirzepatide, including 'clinically proven' and wrong compounder label.

What happened

FDA reviewed altRx’s website in May 2026 and found it offered compounded semaglutide and tirzepatide products. FDA said the pictured labels name “altRx” as if altRx were the compounder when it is not, and the site used claims such as “clinically proven” for compounded products that are not FDA-approved.

What FDA found

  1. FDA said the website’s pictured labels show “altRx” as if altRx made the compounded semaglutide and tirzepatide products, but it is not the compounder.

    FD&C Act § 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)
  2. FDA said claims that the compounded products are “clinically proven” are false or misleading because compounded drug products are not FDA-approved.

    FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]
  3. FDA said putting these products into interstate commerce is a prohibited act because of the misleading claims.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]
  4. FDA said receiving, delivering, or offering to deliver these products in interstate commerce is also prohibited.

    FD&C Act § 301(c) [21 U.S.C. § 331(c)]

What FDA wants

FDA tells altRx to email a written response to FDA’s Office of Compounding Quality and Compliance within 15 business days with corrective steps and documentation, including identifying the entities that produce the compounded drugs, giving sample labeling, and addressing or removing the misleading website claims.

Who should pay attention

  • telehealth and online pharmacy sites selling compounded GLP-1 drugs
  • compounders whose products are promoted by resellers or marketers
  • pharmacies and brands using 'clinically proven' claims for compounded drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low